Close
Back to ADMS Stock Lookup

Adamas Pharma (ADMS) – Business Wire

Oct 8, 2021 04:15 PM Adamas Announces New Employment Inducement Grants
Oct 1, 2021 09:15 AM Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
Sep 16, 2021 09:15 AM Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress
Sep 10, 2021 05:00 PM Adamas Announces New Employment Inducement Grants
Aug 30, 2021 04:11 PM Adamas to Present at Upcoming September Investor Conferences
Aug 13, 2021 04:16 PM Adamas Announces New Employment Inducement Grant
Aug 9, 2021 04:01 PM Adamas Reports Second Quarter 2021 Financial Results
Aug 2, 2021 04:02 PM Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021
Jul 22, 2021 09:15 AM Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
Jul 9, 2021 04:05 PM Adamas Announces New Employment Inducement Grant
Jul 8, 2021 04:02 PM Adamas to Present at Upcoming William Blair Biotech Focus Conference
Jun 23, 2021 04:42 PM Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 11, 2021 04:08 PM Adamas Announces New Employment Inducement Grant
Jun 10, 2021 09:15 AM New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease
May 27, 2021 04:11 PM Adamas to Present at Upcoming June Conferences
May 10, 2021 04:02 PM Adamas Reports First Quarter 2021 Financial Results
May 7, 2021 04:05 PM Adamas Announces New Employment Inducement Grant
Apr 29, 2021 04:04 PM Adamas to Present at Upcoming BofA Conference
Apr 27, 2021 09:15 AM Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners
Apr 26, 2021 04:04 PM Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021
Apr 19, 2021 09:15 AM Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting
Apr 15, 2021 09:15 AM Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
Apr 7, 2021 05:19 PM Adamas to Present at Upcoming Needham Conference
Mar 29, 2021 09:15 AM Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease
Mar 5, 2021 04:02 PM Adamas Announces New Employment Inducement Grant
Mar 1, 2021 04:04 PM Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 24, 2021 09:16 PM Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
Feb 24, 2021 04:08 PM Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
Feb 23, 2021 04:03 PM Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 17, 2021 04:06 PM Adamas to Present at Upcoming Healthcare Conferences
Feb 10, 2021 09:24 AM Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
Feb 1, 2021 02:07 PM Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
Feb 1, 2021 08:01 AM Adamas Announces Settlement of Patent Litigation with Zydus
Dec 19, 2019 08:00 AM E-Scape Bio Appoints Anthony Rimac as Chief Financial Officer and Ann Kapoun, Ph.D., as SVP of R&D

Back to ADMS Stock Lookup